Specifically, the integrated nomogram achieved an AUC of 0.848 for differentiating HER2-zero from HER2-low/HER2-positive cancers, 0.881 for HER2-low versus HER2-positive cancers, and 0.780 for HER2-zero versus HER2-low cancers in the testing cohort. This evidence concerns the gene ERBB2 and cancer.